Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02222610 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
A Phase 2 study, sponsored by Greater Houston Retina Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02222610 is a Phase 2 study that has completed, run by Greater Houston Retina Research. The registered enrollment target is 40 participants.
The verdict
NCT02222610, a Phase 2 study, has completed, sponsored by Greater Houston Retina Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the tolerability and efficacy of ranibizumab treatment administered in subjects with radiation retinopathy
Interventions
- DRUG 0.5 mg ranibizumab
- PROCEDURE Targeted Retinal Photocoagulation (TRP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-09-23 |
| Est. Completion | 2019-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02222610
The ClinicalTrials.gov registry entry for NCT02222610 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Greater Houston Retina Research, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 0.5 mg ranibizumab is the first listed.
NCT02222610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02222610 about?
NCT02222610 is a clinical study titled "Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.". The purpose of this study is to assess the tolerability and efficacy of ranibizumab treatment administered in subjects with radiation retinopathy
What is the current status of trial NCT02222610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2014-09-23. Estimated completion is 2019-03.
What interventions are being tested in trial NCT02222610?
The interventions under investigation include: 0.5 mg ranibizumab (DRUG), Targeted Retinal Photocoagulation (TRP) (PROCEDURE).
Who is sponsoring clinical trial NCT02222610?
This trial is sponsored by Greater Houston Retina Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.